Literature DB >> 11310488

Complications during clinical courses of Pneumocystis carinii pneumonia in patients with acquired immunodeficiency syndrome.

K Teruya1, A Yasuoka, M Yamaguchi, C Yasuoka, Y Yamamoto, I Genka, N Tachikawa, Y Kikuchi, S Oka.   

Abstract

OBJECTIVE: To describe the incidence of complications before and during therapy of Pneumocystis carinii pneumonia (PCP) in patients with acquired immunodeficiency syndrome (AIDS).
METHODS: A retrospective review of the patient's medical records. PATIENTS: A total of 29 patients with AIDS and PCP who were admitted to the AIDS Clinical Center, International Medical Center of Japan from July 1996 to November 1999.
RESULTS: Adverse effects were found in 24 (88.9%) of 27 patients treated with trimethoprim/sulfamethoxazole (T/S), 6 (46.1%) of 13 treated with parenteral pentamidine, and 2 (20%) of 10 treated with inhaled pentamidine. Infectious and/or non-infectious complications were found in 25 (86.2%) of 29 study patients. Regarding infectious complications, 16 (55.2%) were found on admission and 10 cases (34.5%) with infectious complications were identified during admission; including oral candidiasis (37.9% and 17.2%, respectively) and genital herpes (3.4% and 6.9%, respectively). Cytomegalovirus antigenemia was detected in 4 cases (13.8%) on admission and 12 cases (41.4%) during admission. Non-infectious complications affected 11 cases (37.9%) on admission, and 6 cases (20.7%) during admission, the latter included heart failure (10.3%) and pneumothorax (6.9%). PCP was successfully treated in all but one patient who suffered from repeated pneumothorax.
CONCLUSION: Treatment of PCP can be problematic and it is important to be aware of the high incidence of various complications that can occur during the treatment of PCP.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11310488     DOI: 10.2169/internalmedicine.40.221

Source DB:  PubMed          Journal:  Intern Med        ISSN: 0918-2918            Impact factor:   1.271


  3 in total

1.  Structure and inhibition of human diamine oxidase.

Authors:  Aaron P McGrath; Kimberly M Hilmer; Charles A Collyer; Eric M Shepard; Bradley O Elmore; Doreen E Brown; David M Dooley; J Mitchell Guss
Journal:  Biochemistry       Date:  2009-10-20       Impact factor: 3.162

2.  Pneumomediastinum, pneumorrhachis, and subcutaneous emphysema in Pneumocystis jiroveci pneumonia in AIDS.

Authors:  Nasir Saleem; Sanober Parveen; Chibuzo Odigwe; Nkemakolam Iroegbu
Journal:  Proc (Bayl Univ Med Cent)       Date:  2016-04

3.  Clinical impact of pneumothorax in patients with Pneumocystis jirovecii pneumonia and respiratory failure in an HIV-negative cohort.

Authors:  Ji Soo Choi; Se Hyun Kwak; Min Chul Kim; Chang Hwan Seol; Sung Ryeol Kim; Byung Hoon Park; Eun Hye Lee; Seung Hyun Yong; Ah Young Leem; Song Yee Kim; Sang Hoon Lee; Kyungsoo Chung; Eun Young Kim; Ji Ye Jung; Young Ae Kang; Moo Suk Park; Young Sam Kim; Su Hwan Lee
Journal:  BMC Pulm Med       Date:  2022-01-08       Impact factor: 3.317

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.